INNOVATIVE THERAPIES BASED ON A NEXT-GENERATION DRUG DELIVERY PLATFORM

About Us

At MDimune, we are passionate about changing the world by developing innovative therapeutics.

History

FOUNDATION ~ 2019
2019
12
  • Certified for the Excellence in Employee Invention Promotion by the Korean Intellectual Property Office
06
  • Signed an investment contract with The Wells Investment
05
  • Received investments from institutional investors (QUAD Investment Management, STIC VENTURES, KCLAVIS Investment, DAYLI Partners, InterValue Partners)
02
  • Recruited Dr. Seung Wook Oh as a Chief Scientific Officer
01
  • Awarded a Youth-friendly Enterprise certification by the Ministry of Employment and Labor
2018
12
  • Awarded a Post-TIPS (Tech Incubator Program for Startup) grant and Global Marketing grant
05
  • Signed investment contract with STIC Investments Inc.
  • Selected as a designated company for alternative military services by Seoul Regional Military Manpower Administration
04
  • Selected for an Exclusive Consultant Support project for Innovative Biotherapeutics R&D by Korea Food and Drug Administration
03
  • Awarded the grand prize for the biotech division of the Korea Industrial Enterprise Award by Money Today for the second consecutive year
  • Signed investment contracts with The Wells Investment, Invest Korea, LNS Venture, and InterValue Partners
2017
12
  • Signed a joint development agreement with Institute for Refractory Cancer Research at Samsung Medical Center for brain cancer therapeutics
11
  • Signed a joint development agreement with Hypoxia-related Disease Research Center at Inha University Medical School for brain disease therapeutics
03
  • Received the grand prize for the biotech division of the Korea Industrial Enterprise Award by Money Today
  • Signed a business agreement with KBIO Center for New Drug Development at Osong
01
  • Signed an MOU with Hanlim Pharmaceuticals Inc. for development of age-related macular degeneration therapeutics
  • Signed an MOU with SCM Lifescience for co-development of atopy therapeutics
2016
10
  • Relocated the headquarters and research center
09
  • Awarded a TIPS (Tech Incubator Program for Startup) grant by the Small and Medium Business Administration
  • Selected for an Investors-linked R&D project by Ministry of Trade, Industry and Energy
08
  • Received investments, including Institutional Investors
05
  • Launched an MDimune R&D center under Korea Industrial Technology Association
03
  • Selected for TIPS (Tech Incubator Program for Startup) by the Small and Medium Business Administration
  • Signed investment contract with Innopolis Partners, LLC
2015
10
  • Certified as a venture company by Korea Technology Finance Corporation
05
  • Signed a technology transfer agreement, “Proprietary drug delivery technology based on artificial exosome”
04
  • Founded MDimune Inc.

Certification Status

/
/
trademark registration
DDS4.0
(the United States of America)
상표등록
DDS4.0
(대한민국)
상표등록
엠디뮨
(대한민국)
상표등록
Bionanosome
(대한민국)
상표등록
바이오드론
(대한민국)
상표등록
BioDrone
(대한민국)
trademark registration
BioDrone
(the United States of America)
商標登録
BioDrone
(日本)
/